Viking plans to explore monthly dosing for ... for weight loss in the ongoing VENTURE trial for oral VK2735. Brian Lian ...

During their Q4 earnings call, CEO Brian Lian reaffirmed Viking's intention to launch VK2735 as an auto-injector. We do plan to introduce an auto-injector in the Phase 3 program. So we would ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...

According to Viking, the collaboration will leverage CordenPharma’s expertise in peptide drug substance, sterile injectables, and oral solid dosage manufacturing to facilitate scalability and supply ...

The data released by Viking showed that adults taking the highest ... effective maintenance of weight control," said Viking CEO Brian Lian, Ph.D., in a statement. Profit and prosper with the ...

“The first quarter of 2024 was an exceptional period for Viking,” stated Brian Lian, Ph.D., president and CEO of Viking. “During the quarter, the company reported positive top-line results ...

Viking Therapeutics (VKTX), the developer of ... anticipate will be significant commercial demand,” said Viking CEO Brian Lian in a press release. Despite the news, Viking’s stock fell over ...

These API and final finished product capacities are further expandable at Viking's option. "We are excited to enter into this agreement with one of the world's leading CDMOs in the peptide space," ...

Brian Lian, Ph.D., CEO of Viking Therapeutics, expressed confidence in CordenPharma’s ability to meet the anticipated significant commercial demand for VK2735 due to their established presence ...

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian ...